| Shirley Ann Holck, | |
|
705 N 9th St, Arlington, NE 68002-3032 | |
| (402) 478-4121 | |
| Not Available |
| Full Name | Shirley Ann Holck |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 705 N 9th St, Arlington, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184107914 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 51251 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Shirley Ann Holck, 705 N 9th St, Arlington, NE 68002-3032 Ph: (402) 478-4121 | Shirley Ann Holck, 705 N 9th St, Arlington, NE 68002-3032 Ph: (402) 478-4121 |
News Archive
Xcorporeal, Inc. (Pink Sheets: XCRP) (the "Company" or "Xcorporeal") announced that, effective as of today, the Company's common stock commenced trading on the Pink Sheets Electronic OTC Market, an inter-dealer electronic quotation service for securities traded over-the-counter also known as the Pink Sheets, under the symbol "XCRP".
Young adults diagnosed with attention deficit/hyperactivity disorder (ADHD) in adolescence show differences in brain structure and perform poorly in memory tests compared to their peers, according to new research from the University of Cambridge, UK, and the University of Oulu, Finland.
According to information in the article, more than 40,000 new cases of head and neck cancer are diagnosed annually in the United States, with 12,000 deaths each year. Patients with head and neck cancer often experience problems with eating and communicating, have pain, and have poor emotional well being and general functional status.
A research team from the Laval Centre de sant- et de services sociaux, Universit- de Montr-al and McGill University Health Centre has examined the benefits of greater collaboration between family physicians and community pharmacists for select patients.
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon- (interferon beta-1b), Copaxone- (glatiramer Acetate) or Rebif - (interferon beta-1a).
› Verified 3 days ago
Loretta Hilgenkamp, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 20703 County Road 24, Arlington, NE 68002 Phone: 303-501-4401 |